ArticleJournal of primary care & community health
Hospital-at-Home for Alcohol and Substance Use Disorders Compared to Inpatient Treatment in Dual Diagnosis Patients: A Retrospectively Matched Cohort Pilot Study Incorporating Service Use 12 months Pre- and Post-Treatment in Geneva.
Article in Journal of primary care & community health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis quasi-experimental study investigates the effects of the first-ever home treatment (HT), equivalent to inpatient care, for individuals with dual diagnoses: severe alcohol and/or substance use disorder plus major psychiatric illness. Outcomes are compared to those of regular inpatient treatment (IT) of the same addiction service. The primary objective was to evaluate feasibility and safety of HT. Secondary outcomes measures included discontinuation of treatment and service utilization during the 12-month follow-up period as defined by the number of emergency department visits and hospitalization days.
methodsOur Geneva model was introduced to meet local needs. In 2023, 39 individuals received home treatment (HT) for the first time, either in their own homes or in residential settings. They were retrospectively compared to a group of individuals who had undergone regular IT. Matching was based on age and gender. Allocation to IT or HT was determined by individual preferences as well as predefined inclusion and exclusion criteria following an evaluation interview. Electronic patient records were reviewed 1 year later to collect data on service use.
resultsThe primary outcome criteria were met. Treatment withdrawal occurred among IT patients only. At 1-year follow-up, a clear difference in addiction-related hospital days emerged in favor of HT, with smaller but still favorable for HT differences for sequelae and somatic problems. At intake, the HT and IT groups differed regarding stimulant and opioid use, as well as in the presence of the exclusion criteria history of complicated withdrawal and suicidality, which were only present in the IT group. Health of the Nations Outcome Scale (HoNOS) scores at admission and discharge did not differ between groups. Sociodemographic factors showed small differences for partnership status and housing, more pronounced ones for employment, in favor of HT patients.
conclusionsThis first study on HT for dual-diagnosis patients suggests that such treatment is feasible and safe, as demonstrated for HT in general psychiatry, and may offer certain advantages over inpatient care. Key limitations include the lack of randomization, the retrospective design, limited statistical power, and the fact that data can currently only be compared with HT from general adult psychiatry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.